Cas:910058-11-6 N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine manufacturer & supplier

Chemical Name:N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine

CAS.NO:910058-11-6

Synonyms:[1,1′-Biphenyl]-4,4′-diamine, N4,N4′-bis[4-(diphenylamino)phenyl]-N4,N4′-di-1-naphthalenyl-;1,4-Benzenediamine, N,N-[1,1′-biphenyl]-4,4′-diylbis[N-1-naphthalenyl-N,N-diphenyl-;N,N’-Bis[4-(diphenylamino)phenyl]-N,N’-di(1-naphthyl)-4,4′-biphenyldiamine;N,N’-bis[4-(diphenylamino)phenyl]-N,N’-dinaphthalen-1-ylbiphenyl-4,4′-diamine

Molecular Formula:C₆₈H₅₀N₄

Molecular Weight:923.151

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.2±0.1 g/cm3

Index of Refraction:1.741

PSA:12.96000

Exact Mass:922.403564

LogP:20.52

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [1,1′-Biphenyl]-4,4′-diamine, N4,N4′-bis[4-(diphenylamino)phenyl]-N4,N4′-di-1-naphthalenyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N’-bis[4-(diphenylamino)phenyl]-N,N’-dinaphthalen-1-ylbiphenyl-4,4′-diamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-Benzenediamine, N,N-[1,1′-biphenyl]-4,4′-diylbis[N-1-naphthalenyl-N,N-diphenyl- Use and application,N,N’-Bis[4-(diphenylamino)phenyl]-N,N’-di(1-naphthyl)-4,4′-biphenyldiamine technical grade,usp/ep/jp grade.

Related News: f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine manufacturer This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine supplier f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. N-[4-[4-[[4-(diphenylamino)phenyl]-(1-naphthyl)amino]phenyl]pheny l]-N-(1-naphthyl)-N’,N’-diphenyl-benzene-1,4-diamine factory Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.